Tracking tumor-specific CD8⁺ T cell responses.

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Melanoma treatment often involves immunotherapy, such as anti-PD-1 therapy.
• Identifying specific targets for T cell responses is crucial for effective cancer therapies.

Purpose of the Study:

• To computationally predict and experimentally validate neoantigen-specific T cell responses in melanoma patients.
• To identify key neoantigens associated with response to anti-PD-1 therapy.
• To engineer T cells for potential cellular therapy applications.

Main Methods:

• Computational prediction of neoantigens.
• Experimental validation of T cell responses.
• T cell receptor (TCR) engineering.
• Analysis of patient immune responses.

Main Results:

• A restricted set of neoantigens was identified as being recognized by polyclonal CD8+ T cells.
• These neoantigens were found to be a unique feature in patients responding to anti-PD-1 therapy.
• Autologous tumor-responsive T cells expressing neoantigen-specific TCRs were successfully engineered.

Conclusions:

• Neoantigen recognition by T cells is a key factor in anti-PD-1 therapy response in melanoma.
• Engineered T cells targeting specific neoantigens represent a viable strategy for future cellular therapies.
• This study provides a proof-of-concept for neoantigen-directed T cell-based cancer treatments.